Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. - Wikidata - wikimedia - TriplyDB

Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women.

Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women.

http://www.wikidata.org/entity/Q34038946

about

Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140.Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.Seroprevalence of 8 oncogenic human papillomavirus genotypes and acquired immunity against reinfection Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections.Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins Increased plasma levels of adipokines and inflammatory markers in older women with persistent HPV infection.HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial.Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection.A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study.Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus Detecting cancers through tumor-activatable minicircles that lead to a detectable blood biomarker.Secreted blood reporters: insights and applications.A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection.Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine A comparative study of two different assay kits for the detection of secreted alkaline phosphatase in HPV antibody neutralization assays.Therapeutic cancer vaccines: current status and moving forward.Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera.Oral Immunoglobulin Levels are Not a Good Surrogate for Cervical Immunoglobulin Levels Development of a simple and quick immunochromatography method for detection of anti-HPV-16/-18 antibodies.Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials.Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®)Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids Human papillomavirus infection in the oral cavity of HIV patients is not reduced by initiating antiretroviral therapy.Differences in the concentration and correlation of cervical immune markers among HPV positive and negative perimenopausal women Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination.Determinants and correlation of systemic and cervical concentrations of total IgA and IgG.Comparison of antibody responses to human papillomavirus vaccination as measured by three assays.Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.HPV disease transmission protection and control.Assessment of mucosal immunity to HIV-1.Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.Functional assessment and structural basis of antibody binding to human papillomavirus capsid.The prevalence of HPV infections in HPV-vaccinated women from the general population.Therapeutic Cancer Vaccines.Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development.

P2860

Q31076192-9A612DCD-9BE8-4CB1-98B8-3A0DEFC51149 Q33723312-0CC6941D-DC28-47E9-ACAD-79AEEDFEB555 Q33947813-4BDB84EF-8753-4DD2-88DF-3E2887936763 Q34032367-7B347ED3-1FA0-491E-8B53-F51D60B35877 Q34267472-9D24E1AD-3786-4E04-ACC9-7A7ADAEDE37E Q34492140-E070C214-D75B-4BCD-83EE-C7DD6230B2F5 Q34553461-E567BBC4-8910-43FC-9B0F-C0FC05D60E0D Q34612818-9E226219-774B-4CE9-93EF-D45DFA6CE3A6 Q34708325-722048B9-96BD-4110-86E1-747335BE8E7C Q34738944-0D1271B3-3EC6-4DB5-85B8-F36CC13F7E38 Q34786808-D4687A92-F6C1-4CAB-BBE2-704A2ADADC91 Q35088658-F77AE952-06EA-429C-8C4B-392BADA7C3FD Q35109451-E825DEC3-A71E-4B9E-A085-BED7406AB86C Q35190027-61E9C0CC-8A20-4A4F-9669-0B1590DB4016 Q35294368-9383D043-8ECB-4A77-BD8D-D2B601D7C09E Q35599310-8756C242-5D82-4A2F-BE6F-C48071FEA9DB Q35818648-5153A7A6-7A68-4124-BA6F-6C1660FF2FB6 Q35887709-0F51D946-66E2-4054-AA63-43FF09EE2F16 Q35894347-66FA17A7-723B-46D4-8194-069F1F016086 Q35985515-109E74A4-686E-47BC-B4DD-6744D68269F5 Q36054504-63CA2F17-A95F-4DF6-881C-42BA7DDBCB4D Q36269739-216A313F-1994-45D8-A0E4-A12AED8CAAE8 Q36305499-B52DF776-AAF0-4B2C-842A-C3D5F20CC999 Q36480943-1B2A2D77-5012-4CC1-AB46-F8F8D74DEF7C Q36750553-0BFE1076-019B-46EC-8185-1F68E5269D00 Q36988090-04A7B637-DE0D-446A-9ED5-98170C21AE02 Q37318334-5C0C10BB-970C-4DD9-ACCA-845588C2C8B4 Q37384735-C5C54DF4-001F-4651-91B0-2A331FBB7E0A Q37388424-A10AFF4B-DA88-43CE-B4F7-34A7C7F50149 Q37466826-5D7586BA-9284-436E-BC74-BE55EF1D95E4 Q37671423-D4609F04-7FBE-4BAD-BFE3-7D9070F19F23 Q37683122-2B8A71CB-5A32-4983-9F0B-573572DA6551 Q37705703-0A346F35-8B20-4835-A546-D6A12572A131 Q37724856-A8299D02-FE84-4F09-8A9F-C3F8A8785016 Q37867102-2CA8A528-1E20-407A-AF05-DFF2415A916A Q38671633-5EBA4962-E22F-4678-9923-EAA1F9950371 Q40291505-2648A071-831D-4225-BDB6-3EF13B3A35EE Q40728648-46F17AA2-07C9-4D50-B727-A10AF101DBFB Q47549756-50DE1A6B-4780-47FB-A67E-0B8B664ED29D

P2860

Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women.

http://www.wikidata.org/entity/Q34038946

description

2008 nî lūn-bûn

@nan

2008 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Evaluation of systemic and muc ...... sponses from vaccinated women.

@ast

Evaluation of systemic and muc ...... sponses from vaccinated women.

@en

Evaluation of systemic and muc ...... sponses from vaccinated women.

@nl

type

label

Evaluation of systemic and muc ...... sponses from vaccinated women.

@ast

Evaluation of systemic and muc ...... sponses from vaccinated women.

@en

Evaluation of systemic and muc ...... sponses from vaccinated women.

@nl

prefLabel

Evaluation of systemic and muc ...... sponses from vaccinated women.

@ast

Evaluation of systemic and muc ...... sponses from vaccinated women.

@en

Evaluation of systemic and muc ...... sponses from vaccinated women.

@nl

P1433

Q34038946-48F775CE-4970-4D20-A0E8-40360841D85E

P1476

Q34038946-66C9E006-BB4A-426E-9F3F-EA58F7DEEE25

P2093

Q34038946-016495CF-9CDC-4689-8072-0586F7F2C8C6

Q34038946-59BE319A-1658-4AEE-941E-D527E6508EEF

Q34038946-5D63E7AD-A35E-489E-8C74-32068DCB49E5

Q34038946-77756BFB-A8B4-4DE4-A9A1-BB77F02039BB

Q34038946-7D552CDA-CE1C-4938-A543-3EBC83729F17

Q34038946-A53FA931-5241-4014-BE4C-5DE237B5F7DA

Q34038946-B4F41997-AC1A-4A6A-90B9-76A489273F23

Q34038946-CEC81EB7-52E8-4916-A067-6519DB52A13F

Q34038946-D305B7FD-0D13-466A-89D4-4901427D11A5

Q34038946-FA8AA009-4B6F-435F-84C4-ED327B283CD1

P2860

Q34038946-08B7F7D0-3A8E-46A1-BB94-9B621CDCA414

Q34038946-0ACEC03A-C0FD-418E-92A9-9C56B67F1295

Q34038946-15EC6A34-EE33-454C-A1FE-358846CE35CD

Q34038946-174F4B8B-3CAC-40A7-AA5A-F10C04ADD06B

Q34038946-1AE6F12F-7CC1-4493-AAA4-E03F849948D7

Q34038946-21703512-3FB0-454B-AE7A-BC0163624057

Q34038946-2674402F-2570-4ABE-97B2-AEBE86E0335B

Q34038946-30931AEA-D881-4779-8485-1816FB0D5FE2

Q34038946-3D7E4F3C-1D40-4E2C-9395-9B03DDE0F4B4

Q34038946-589E552B-4E9D-406A-BAC9-BD686CED3C22

P304

Q34038946-5568220D-BDF0-4B1A-9871-D0DFE4B9624C

P31

Q34038946-270A48B3-1753-40B4-865B-B290E9BBA402

P356

Q34038946-67B5DD98-C6ED-44B0-9199-F457611285AE

P407

Q34038946-DE6256BC-2BAF-4767-923A-BDBA5B0D4A04

P433

Q34038946-144500C2-8422-454B-BA2A-2A30B8AF2825

P478

Q34038946-DCFB73B6-27D0-436B-8D32-DB83083D0C79

P50

Q34038946-67734F68-06F3-40DD-BA6E-D9F6664910ED

Q34038946-F7B98067-6A7E-4D1B-BACA-73075690CD09

P577

Q34038946-53494E2E-A83A-4755-BC56-EE4198E374F0

P5875

Q34038946-8646116B-9242-40D5-93DE-DD2809B9B4AE

P698

Q34038946-61323440-0188-4654-892B-B3D001C5FDE8

P921

Q34038946-6F39AD38-353A-49C3-9509-334EC95AE1E7

P932

Q34038946-30649980-4F49-4683-8F67-CF2581827B54

P356

J.VACCINE.2008.04.074

P1433

P1476

Evaluation of systemic and muc ...... sponses from vaccinated women.

@en

P2093

Alfonso García-Piñeres

http://www.w3.org/2001/XMLSchema#string

Carolina Porras

http://www.w3.org/2001/XMLSchema#string

Costa Rica Vaccine Trial (CVT) Group

http://www.w3.org/2001/XMLSchema#string

Francis Dessy

http://www.w3.org/2001/XMLSchema#string

Ligia A Pinto

http://www.w3.org/2001/XMLSchema#string

Rolando Herrero

http://www.w3.org/2001/XMLSchema#string

Roni T Falk

http://www.w3.org/2001/XMLSchema#string

Sandra L Giannini

http://www.w3.org/2001/XMLSchema#string

Sylviane Poncelet

http://www.w3.org/2001/XMLSchema#string

Troy J Kemp

http://www.w3.org/2001/XMLSchema#string

P2860

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

Epidemiologic classification of human papillomavirus types associated with cervical cancer

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.

Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18

Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles.

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group.

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.

P304

3608-3616

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2008.04.074

http://www.w3.org/2001/XMLSchema#string

P407

P433

29-30

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Allan Hildesheim

Ana Cecilia Rodríguez

P577

2008-05-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5314748

http://www.w3.org/2001/XMLSchema#string

P698

18541349

http://www.w3.org/2001/XMLSchema#string

P921

P932

4131294

http://www.w3.org/2001/XMLSchema#string